Terms ending in 2036
Every in-force patent on Genmab A/S's record whose computed term ends in 2036, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,457,735 | Methods of Inducing T Cell Activation by Administering an Antibody Comprising CD40 and 4-1BB (CD137) Binding Domains In force · High confidence | BioNTech SE | In force | High confidence | |
| US 10,927,181 | Agonistic Tumor Necrosis Factor (TNF) Receptor Binding Agents In force · High confidence | BioNTech SE | In force | High confidence | |
| US 12,421,319 | Binding Agents That Bind OX40 (CD134) and Method of Use Thereof to Treat Disease In force · High confidence | BioNTech SE | In force | High confidence | |
| US 12,799,229 | Bispecific and Multispecific Antibodies and Method for Isolation of Such In force · High confidence | Genmab A/S | In force | High confidence | |
| US 11,814,411 | Nucleic Acid Molecules Encoding Binding Agents to CD40 and 4-1BB (CD137) In force · High confidence | BioNTech SE | In force | High confidence | |
| US 10,364,285 | Agents, Uses and Methods for the Treatment of Synucleinopathy In force · High confidence | H. Lundbeck A/S | In force | High confidence | |
| US 10,428,147 | Anti-Sortilin Antibodies, Uses and Methods for Treatment In force · High confidence | H. Lundbeck A/S | In force | High confidence | |
| US 10,479,835 | Agent, Uses and Methods for Treatment In force · High confidence | H. Lundbeck A/S | In force | High confidence | |
| US 10,640,554 | Agents, Uses and Methods for the Treatment of Synucleinopathy In force · High confidence | H. Lundbeck A/S | In force | High confidence | |
| US 10,647,763 | Agents, Uses and Methods for the Treatment of Synucleinopathy In force · High confidence | H. Lundbeck A/S | In force | High confidence | |
| 12 more term ends in 2036 · Pro | |||||
10 of 22 patents shown. Soonest term end first, then patent number.
Pro members see all 22.
4 of these are in force and held by Genmab A/S.
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.